Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of osimertinib with bevacizumab and randomized phase II study of osimertinib with or without bevacizumab in EGFR mutated, T790M positive patients who had progressed EGFR-TKIs (WJOG8715L)

Next Previous
X
Search
Trial Profile

A phase I study of osimertinib with bevacizumab and randomized phase II study of osimertinib with or without bevacizumab in EGFR mutated, T790M positive patients who had progressed EGFR-TKIs (WJOG8715L)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Osimertinib (Primary)
  • Indications Adenocarcinoma; Brain metastases; Lung cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 31 Aug 2021 Status changed from active, no longer recruiting to completed.
    • 21 Sep 2020 Primary endpoint (Phase II: Progression-free survival) has not been met, according to results presented at the 45th European Society for Medical Oncology Congress
    • 21 Sep 2020 Results of phase II part of this trial presented at the 45th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top